| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lymphoma Series: Variants of Large-Cell Lymphoma |
Harvard Medical School, Lymphoma Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Key Words. Anaplastic large cell plymphoma • Lymphomatoid papulosis • Cutaneous lymphoma • ALK
Correspondence: Eric Jacobsen, M.D., Dana-Farber Cancer Institute, Dana 1B30, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-6633; Fax: 617-632-5168; e-mail: Eric_Jacobsen{at}dfci.harvard.edu
Anaplastic large-cell lymphoma, T-/null-cell type (ALCL), is a rare disease that has only been well characterized for two decades. Despite this, the biology of ALCL is better understood than that of many other more common variants of lymphoma. This review focuses on the pathophysiology, clinical presentation, and therapy of ALCL, including stem cell transplantation. In particular, the text emphasizes how novel prognostic features and the evolving understanding of the biology of this disease will influence treatment selection and drug development.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |